GALDERMA
Reinforcing its commitment to advancing dermatology for every skin story, Galderma announced today the formation of a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives through focusing on three key pillars of research, innovation and engagement that play a key role in improving the broad understanding and management of sensitive skin. Comprised of 13 experts from across the world, the group will have representation from diverse geographies including China, Brazil, the Philippines, Germany, France, Australia, Italy and the United States (U.S.).
“We want people to feel in control of their skin, and this is especially important for those who have skin conditions that are often misunderstood – like sensitive skin.
WALTER GEIGER
|
Sensitive skin is a complex and often interconnected condition, requiring personalized care and products specifically designed for it. More than seventy percent of people worldwide diagnose themselves as having sensitive skin, which can negatively impact quality of life and leave them feeling frustrated and looking for better solutions.i There is a need for science-backed guidance and advice on how to identify and care for sensitive skin of all kinds, to help improve the overall quality of sensitive skin.
The Sensitive Skincare Faculty will focus on three core pillars of activities:
- Research – expanding the understanding of sensitive skin by filling evidence gaps and advancing in emerging areas
- Innovation – inspiring the development of new solutions to improve diagnosis and care
- Engagement – enhancing the knowledge of healthcare professionals to shape the future of best practice
In partnership with the Department of Dermatology at the George Washington University School of Medicine and Health Sciences, two grants have been awarded to accelerate the mission of the Sensitive Skincare Faculty. The first will establish a Galderma Sensitive Skin Translational Research Fellowship Program over five years to support medical students interested in expanding their research skill set into sensitive skin. The second project, the Galderma Skin Research Acceleration Fund, will span two years and look specifically at establishing a standard definition of sensitive skin.
“Our goal is to transform the science of sensitive skin into actionable insights and practical advice
PROFESSOR ADAM FRIEDMAN
|
Faculty members include Adam Friedman (co-chair, U.S.), Giovanni Pellacani (Italy), Martina Kerscher (Germany), Aaron Farberg (U.S.), Flávia Alvim Sant’Anna Addor (Brazil), Belinda Welsh (Australia), Yan Wu (China), Flordeliz Abad-Casintahan (Philippines), Adelaide Hebert (U.S.), Xiang Leihong (China), Laurent Misery (France), Joachim Fluhr (Germany) and Leona Yip (Australia).
The faculty’s inaugural meeting took place at the European Academy of Dermatology and Venereology congress in Milan, where members also participated in a Galderma-sponsored symposium on sensitive skin insights and management approaches.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References:
iChen W, Dai R, Li L. The prevalence of self‐declared sensitive skin: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2020 Aug;34(8):1779-88.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005039/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Reinforces its Leadership in eSIM and IoT Connectivity with a ‘Ready to Use’ Certified Solution8.7.2025 08:00:00 CEST | Press release
At a time when billions of connected objects are reshaping industries, Thales has achieved an essential security certification for its eSIM solution, reinforcing its leadership in trusted connectivity management for the Internet of Things (IoT). The certification, granted by the GSMA under the eSIM Security Assurance (eSA) scheme, marks a significant milestone in enabling large-scale, secure, and efficient IoT deployments across industries including smart metering, healthcare, and automotive. This positions Thales as a trusted partner capable of providing full protection against advanced cyber threats — delivering end-to-end security solutions, from chip to cloud, and ensuring compliance with emerging security standards (e.g., the EU Cyber Resilience Act). With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence), businesses and industries face growing pressure to deploy connected devices at scale — securely and efficiently. The SGP.32 IoT specificati
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release
Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime
Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release
Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha
Murata Launches World’s First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G Networks8.7.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the mass production and commercial shipment of the world’s first*1 high-frequency filter using XBAR technology*2. Developed by combining Murata’s proprietary Surface Acoustic Wave (SAW) filter expertise with XBAR technology from Murata's subsidiary Resonant Inc., it enables the extraction of desired signals while achieving both low insertion loss and high attenuation. These features are critical for the latest wireless technologies, including 5G, Wi-Fi 6E, Wi-Fi 7, and emerging 6G technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707682186/en/ [Murata Manufacturing Co., Ltd.] The world’s first high-frequency filter using XBAR technology The demand for reliable high-frequency communications continues to grow in response to the widespread deployment of 5G and the future development of 6G. Simultaneously, wireless local-area network (W
YES Delivers Multiple VertaCure LX Systems7.7.2025 21:34:00 CEST | Press release
Yield Engineering Systems (YES), a leading provider of process equipment for AI and HPC semiconductor applications, today announced the delivery of multiple VertaCure™ LX curing systems to one of Taiwan’s top outsourced semiconductor assembly and test (OSAT) providers. These systems will support advanced packaging processes for Edge Computing and HPC solutions, delivering critical low-temperature curing, annealing, and degassing for WLCSP, Plated Bump, and Cu Pillar applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703001376/en/ VertaCure LX The VertaCure LX is a fully automated vacuum curing and degassing system engineered to ensure uniform temperature distribution and precise control of heating and cooling rates. This results in complete solvent removal, improved film properties, elimination of outgassing after cure, and outstanding particle performance. YES products have consistently demonstrated superior qu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom